Latham & Watkins Advises on Rocket Pharmaceuticals’ Public Offering

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, has announced the pricing of an underwritten public offering of (i) 7,812,500 shares of its common stock at a public offering price of US$16 per share and (ii) to certain investors, pre-funded warrants to purchase 3,126,955 shares of common stock at a price of US$15.99 per pre-funded warrant, which represents the per share public offering price for the common stock less the US$0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Rocket from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately US$175 million. All shares and pre-funded warrants in the offering are to be sold by Rocket. In addition, Rocket has granted the underwriters a 30-day option to purchase up to an additional 1,640,918 shares of its common stock. The offering is expected to close on or about September 15, 2023, subject to customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a corporate team led by New York partner Nathan Ajiashvili, with associates Matthew DeSilva, Egzon Sulejmani Jie Lin Nai and Richard Dacher.